RxDoctor Payments Data

Tory McJunkin, MD

Pain Medicine · Scottsdale, AZNPI 1093850323

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (55.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Nevro Corp. accounts for 90.9% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2019 at $70,785 and has fallen 92.4% since, to $5,361 in 2025. Among pain medicine clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$204,353in general payments, 2019–2025

Across 451 payments — averaging $453.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$186K
  • Omnia Medical, LLC$7K
  • Globus Medical$5K
  • Axonics, Inc.$3K
  • Boston Scientific$1K
  • Abbott$843
  • plus $1K from 16 others
$13,491in research payments, 2019–2025

Across 84 payments — averaging $160.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biotronik Inc.$7K
  • Saluda Medical Americas, Inc.$4K
  • Abbott$2K

What the payments were for

  • Consulting fees$50,28025%
  • Speaking & faculty fees$113,53356%
  • Travel & lodging$27,58313%
  • Food & beverage$12,9586%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$204,353 in reported general payments places this provider in the 95th percentile of 180 pain medicine providers in Arizona.

See all pain medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$122,116
Medicare patients
230
Services billed
806

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cefadroxil97$412
Oxybutynin Chloride28$46

Paid to pharmacies, not to this prescriber.

Other pain medicine in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →